News releases
50 of 53 items
Award of Share Options 21 Sep 2007
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical group focused on the development of medicines for the treatment of neuro-developmental disorders, announces that on 19 September 2007, the Company's Executive Directors were awarded share options by the Company's Remuneration Committee, which is comprised wholly of Non-Executive Directors. Options have been granted to Neuropharm's Chief Executive Officer, Robert Mansfield, and its Chief Financial Officer, Graham Yeatman, under the Company's Share Option Scheme (the 'Scheme'). These grants were part of the annual, company-wide performance-based remuneration review.
Preliminary results for the year ended 30 June 2007 20 Sep 2007
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical group focused on the development of medicines for the treatment of neuro-developmental disorders, is pleased to announce its maiden preliminary results for the year ended 30 June 2007.
Notice of Maiden Preliminary Results And Disclosure of information required by AIM Rule 26 17 Aug 2007
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical group focused on the development of products for the treatment of disorders of the central nervous system (CNS), will announce its maiden Preliminary Results for the year ended 30 June 2007, on Thursday 20 September 2007.
Collaboration with Autism Speaks 5 Jul 2007
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical group focused on the development of products for the treatment of disorders of the central nervous system (CNS), is pleased to announce that it has signed a collaboration agreement with the influential US charitable organisation Autism Speaks in preparation for a planned multi-centre trial of NPL-2008, the Company's custom-designed product for the treatment of autism.
Total Voting Rights 8 May 2007
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on the development of products for the treatment of disorders of the central nervous system (CNS), announces that, for the purpose of the Financial Services Authority's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this notice is 31,536,697.
Neuropharm Limited's interim results for the six months ended 31 December 2006 21 Mar 2007
Neuropharm Group plc (AIM: NPH), the speciality pharmaceutical group focused on the development of drugs for the treatment and management of developmental and degenerative disorders of the central nervous system (CNS), is pleased to announce the results of Neuropharm Limited, its wholly owned trading subsidiary, for the six months ended 31 December 2006, the period prior to Neuropharm Group plc's flotation on the AIM market of the London Stock Exchange on 6 March 2007.
Completion of Second Admission 7 Mar 2007
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical group focused on the development of products for the treatment of disorders of the central nervous system (CNS), is pleased to announce the admission to trading on AIM of the Ordinary Shares issued to non-VCT investors in the Placing announced on 1 March 2007 associated with the Company's Initial Public Offering.
First Day of Dealings on AIM Admission of non-VCT shares on 7 March 2007 1 Mar 2007
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical group focused on the development of products for the treatment of disorders of the central nervous system (CNS), is pleased to announce that its existing Ordinary Shares, and the Ordinary Shares issued to VCT investors in the recent Placing that raised £20.0 million (gross), have today been admitted to trading on AIM. Dealings are expected to commence on AIM at 8.00am tomorrow in the Ordinary Shares issued to non-VCT investors in the Placing. Neuropharm's ticker symbol is NPH.
FDA Grants Neuropharm Orphan Drug Designation 28 Feb 2007
Neuropharm Group Plc, a speciality pharmaceutical group focused on the development of products for the treatment of developmental and degenerative disorders, is pleased to now be able to announce that the US Food and Drug Administration Office of Orphan Product Development has previously granted Neuropharm Orphan Drug Designation (ODD) for the use of its compound NPL-2009 (fenobam) in the treatment of Fragile X Syndrome.
Dr Graeme Hart Appointed as Chairman 1 Dec 2006
Neuropharm, the speciality pharmaceutical group focused on products for the treatment and management of developmental and degenerative disorders, is pleased to announce the appointment of Dr Graeme Hart as Chairman, with immediate effect.
50 of 53 items